Search company, investor...

Founded Year

2009

Stage

Line of Credit | Alive

Total Raised

$232.57M

Last Raised

$15M | 1 yr ago

About HistoSonics

HistoSonics develops a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors at sub-cellular levels. The company is focused on the development of its Edison platform, combining imaging with sensing technology to deliver personalized external beam treatments with precision and control, reducing the side effects of conventional therapies. The company was founded in 2009 and is based in Minneapolis, Minnesota.

Headquarters Location

16305 36th Ave N Suite 300

Minneapolis, Minnesota, 55446,

United States

612-351-0361

Loading...

Loading...

HistoSonics Patents

HistoSonics has filed 15 patents.

The 3 most popular patent topics include:

  • medical physics
  • medical ultrasonography
  • ultrasound
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/27/2019

11/14/2023

Medical physics, Radiation therapy, Ultrasound, Inflammations, Medical ultrasonography

Grant

Application Date

11/27/2019

Grant Date

11/14/2023

Title

Related Topics

Medical physics, Radiation therapy, Ultrasound, Inflammations, Medical ultrasonography

Status

Grant

Latest HistoSonics News

08:30 ET Introworks Launching Agency Provides Marketing Communications Expertise to HistoSonics® as Revolutionary Med Tech Produ...

Nov 28, 2023

News provided by Share this article Share toX MINNEAPOLIS, Nov. 28, 2023 /PRNewswire/ -- Introworks, a leading marketing communications agency, is proud to have supported HistoSonics on the launch of their Edison® System – an unprecedented medical technology that is predicted to revolutionize the treatment of tumors and unwanted tissue, starting in the liver. The collaboration leveraged Introworks' expertise in strategic messaging, storytelling and breakthrough creative to ensure this groundbreaking medical technology receives the attention it deserves. HistoSonics, founded in 2010, is poised to change patient care and treatment options featuring a mechanical-only method of destroying tumors and tissues called histotripsy. The Edison® System uses an image-guided sonic beam therapy (histotripsy) combined with advanced imaging  to deliver non-invasive, personalized treatments to targeted liver tissue and tumors with precision and control and without needles, knives, or ionizing radiation. "We are thrilled to have the opportunity to work closely with HistoSonics in launching this extraordinary new medical technology," said Bob Freytag, CEO of Introworks. "Our team understands the unique challenges medical start-ups face and are deeply committed to crafting powerful narratives that resonate and drive meaningful engagement. This product is especially rewarding because it allows us to directly contribute through our partnership to advancing a revolutionary medical technology." The marketing communications expertise provided by Introworks included supporting HistoSonics in refining the overarching product strategic narrative and supporting collateral such as animations, website, and print pieces, as well as staffing support in the form of a Fractional Launch Navigator. Introworks Fractional Launch Navigators offer flexible marketing staffing support to ensure that critical launches and initiatives meet company timelines and goals. "Introworks has been a great partner in the launch preparation of our Edison® System, providing expertise in content creation and launch execution," said Josh King, VP of Marketing at HistoSonics. The Introworks team spent valuable time and effort early on gaining an in-depth understanding of our launch needs and the dynamics of our regulatory landscape. This foundation yielded a strategic and creative approach that has us poised to meet our overall goals for this  launch." This launch opens up a new category of care for patients and an innovative treatment option for patients suffering with liver tumors., This contemporary experience with HistoSonics only solidifies Introworks' position as a leading partner for medical innovators who want to win in dynamic, high potential markets. About Introworks: Introworks is a marketing communications agency that specializes in launching, rebooting and boosting products and services that impact health, well-being and the world we live in. Medical innovators find success in their ability to simplify complex concepts and change conversations to help companies win in tough market situations. About HistoSonics, Inc: HistoSonics' image guided sonic beam therapy system uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control. The science of histotripsy uses focused sound energy to produce controlled acoustic cavitation that mechanically destroys and liquifies targeted liver tumors at sub-cellular levels. The company believes that the novel mechanism of action of their proprietary technology provides significant advantages to patients, including the ability of the treatment site to recover and resorb quickly. Uniquely, the HistoSonics' platform also provides physicians the ability to monitor the destruction of tissue under continuous real-time visualization and control, unlike any modality that exists today. SOURCE Introworks

HistoSonics Frequently Asked Questions (FAQ)

  • When was HistoSonics founded?

    HistoSonics was founded in 2009.

  • Where is HistoSonics's headquarters?

    HistoSonics's headquarters is located at 16305 36th Ave N, Minneapolis.

  • What is HistoSonics's latest funding round?

    HistoSonics's latest funding round is Line of Credit.

  • How much did HistoSonics raise?

    HistoSonics raised a total of $232.57M.

  • Who are the investors of HistoSonics?

    Investors of HistoSonics include Venture Investors, State of Wisconsin Investment Board, Lumira Ventures, Johnson & Johnson Innovation, Yonjin Venture and 12 more.

  • Who are HistoSonics's competitors?

    Competitors of HistoSonics include ADVOS, Aethlon Medical, Uptake Medical, Magneceutical Health, Pathway Medical Technologies and 7 more.

Loading...

Compare HistoSonics to Competitors

Aethlon Medical Logo
Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier - medical device that aims to treat infectious disease.

P
Paragon Intellectual Properties

Nexeon MedSystems is committed to improving lives through the development of therapies for people with cardiovascular disease. With proven medical device research and development talent, a strong intellectual property portfolio and the leadership of a veteran interventional cardiologist, Nexeon has created an pipeline of products for unmet clinical needs.

A
Artenga

Artenga is a company that focuses on the development of platform drug delivery technology in the medical sector. The company's main offerings include non-invasive, targeted drug delivery to the brain and immunotherapy, which involves activating the body's natural defenses against cancer. Artenga primarily serves the healthcare industry, particularly in areas related to serious diseases. It is based in Ontario, Canada.

V
Valor Medical

Valor Medical is a San Diego-based medical device company that has developed liquid embrolic technology for the treatment of cerebral aneurysms.

M
Mercator MedSystems

Mercator MedSystems is a medical technology company that focuses on the treatment of peripheral artery disease. The company offers catheter-guided, microfluid injection systems for site-specific, non-systemic delivery of therapeutic agents directly across any blood vessel, providing efficient and targeted treatment for vascular diseases. The technology also finds application in the treatment of hypertension, oncology, and regenerative medicine. Mercator MedSystems was formerly known as EndoBionics. It was founded in 1999 and is based in Emeryville, California.

A
ADVOS

ADVOS, developed by ADVITOS, is a company focused on the healthcare sector, specifically in the field of intensive care treatment. The company's main offering is a certified innovative treatment for multi-organ failure in intensive care units, which simultaneously supports the kidney, liver, and lung functions, and also regulates the pH of the blood. The primary customers of ADVOS are likely to be healthcare providers in the intensive care industry. ADVOS was formerly known as Hepa Wash. It was founded in 2004 and is based in Munich, Germany.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.